Cross Country Healthcare Merger Clears Key Regulatory Hurdle, Q3 Close Expected
CCRN sits 78% above its 52-week low of $7.43 on elevated volume (1.9× avg).
Summary
The HSR waiting period for Cross Country Healthcare's acquisition by Knox Lane has expired, satisfying a major regulatory closing condition. This follows the definitive merger agreement announced in early May for $13.25 per share and the recent filing of the definitive proxy statement for the shareholder vote. The expiration of HSR approval significantly de-risks the all-cash transaction, moving it closer to completion. Shareholders are scheduled to vote on July 16, 2026, with the deal still expected to close in Q3 2026.
At the time of this announcement, CCRN was trading at $13.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.5M. The 52-week trading range was $7.43 to $14.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.